These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33892054)

  • 21. Modeling particle shape-dependent dynamics in nanomedicine.
    Shah S; Liu Y; Hu W; Gao J
    J Nanosci Nanotechnol; 2011 Feb; 11(2):919-28. PubMed ID: 21399713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures.
    Murugan K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
    Int J Nanomedicine; 2015; 10():2191-206. PubMed ID: 25834433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Nano-Bio Interactions in the Kidney: Toward a Better Understanding of Nanoparticle Clearance.
    Wang J; Liu G
    Angew Chem Int Ed Engl; 2018 Mar; 57(12):3008-3010. PubMed ID: 29450950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.
    Cooper DL; Conder CM; Harirforoosh S
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1661-80. PubMed ID: 25054316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ cellular hitchhiking of nanoparticles for drug delivery.
    Udofa E; Zhao Z
    Adv Drug Deliv Rev; 2024 Jan; 204():115143. PubMed ID: 38008185
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Cevaal PM; Ali A; Czuba-Wojnilowicz E; Symons J; Lewin SR; Cortez-Jugo C; Caruso F
    ACS Nano; 2021 Mar; 15(3):3736-3753. PubMed ID: 33600163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine.
    Kinnear C; Moore TL; Rodriguez-Lorenzo L; Rothen-Rutishauser B; Petri-Fink A
    Chem Rev; 2017 Sep; 117(17):11476-11521. PubMed ID: 28862437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Size-Dependent
    Xu M; Qi Y; Liu G; Song Y; Jiang X; Du B
    ACS Nano; 2023 Nov; 17(21):20825-20849. PubMed ID: 37921488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced Drug Delivery Systems for Renal Disorders.
    Alallam B; Choukaife H; Seyam S; Lim V; Alfatama M
    Gels; 2023 Feb; 9(2):. PubMed ID: 36826285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
    Tyagi P; Subramony JA
    J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Nanoparticle Targeting of the Renal Tubules.
    Williams RM; Shah J; Tian HS; Chen X; Geissmann F; Jaimes EA; Heller DA
    Hypertension; 2018 Jan; 71(1):87-94. PubMed ID: 29133360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney functional stages influence the role of PEG end-group on the renal accumulation and distribution of PEGylated nanoparticles.
    Xin Y; Hou Y; Cong X; Tan H; Wang J; Mao K; Wang X; Liu F; Yang YG; Sun T
    Nanoscale; 2022 Jul; 14(26):9379-9391. PubMed ID: 35727088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in kidney-targeted drug delivery systems.
    Chen Z; Peng H; Zhang C
    Int J Pharm; 2020 Sep; 587():119679. PubMed ID: 32717283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
    Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
    Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced Control of Drug Delivery for
    Crovador R; Heim H; Cottam S; Feron K; Bhatia V; Louie F; Sherwood CP; Dastoor PC; Brichta AM; Lim R; Griffith MJ
    ACS Appl Bio Mater; 2021 Aug; 4(8):6338-6350. PubMed ID: 35006893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicines for renal disease: current status and future applications.
    Kamaly N; He JC; Ausiello DA; Farokhzad OC
    Nat Rev Nephrol; 2016 Dec; 12(12):738-753. PubMed ID: 27795549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.
    Dobrovolskaia MA; Aggarwal P; Hall JB; McNeil SE
    Mol Pharm; 2008; 5(4):487-95. PubMed ID: 18510338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases.
    Jo DH; Kim JH; Lee TG; Kim JH
    Nanomedicine; 2015 Oct; 11(7):1603-11. PubMed ID: 25989200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Nano-War Against Complement Proteins.
    Wang Z; Brenner JS
    AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual and multi-targeted nanoparticles for site-specific brain drug delivery.
    Luo Y; Yang H; Zhou YF; Hu B
    J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.